Beam Therapeutics Inc. (BEAM) company profile
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
About Beam Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Beam Therapeutics Inc. operates as a biotechnology research and development company that develops therapeutic programs and gene editing technologies. The company collaborates with pharmaceutical and biotechnology partners, including Pfizer, Eli Lilly, Apellis Pharmaceuticals, Verve Therapeutics, Orbital Therapeutics, and Prime Medicine. It enters into research agreements, licensing deals, and product development partnerships with academic institutions such as Harvard University and the Broad Institute to discover and advance therapies. Through these collaborative arrangements and development agreements, Beam Therapeutics focuses on advancing experimental therapies and technology platforms alongside its industry and academic counterparties.
The company conducts its operations in the United States and maintains corporate office, laboratory, and manufacturing facilities located in Cambridge, Massachusetts. Beam Therapeutics operates across designated research and development spaces and specialized laboratory facilities to support its operational and scientific pipeline. Its principal executive offices are situated at 238 Main Street in Cambridge, Massachusetts.
Summary of the business section of Beam Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Beam Therapeutics Inc.
- Headquarters
- Cambridge, MA
- Address
- 26 Landsdowne Street 02139
- Phone
- (857) 327-8775
- Website
- beamtx.com
- Employees
- 511, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- BEAM
- Exchange
- Nasdaq
- IPO date
- Feb 7, 2020
- Shares outstanding
- 103M, Jul 28, 2026
- Public float
- $1.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1745999
- CUSIP
- 07373V105
- ISIN
- US07373V1052
- FIGI
- BBG00KXC8646
- Share class FIGI
- BBG00KXC8655
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John M. Evans | CEO, Director | 1,150,205 |
| Bethany J. Cavanagh | SVP, Finance and Treasurer | 50,984 |
| Giuseppe Ciaramella | President | 253,911 |
| Amy Simon | Chief Medical Officer | 85,696 |
| Christine Bellon | Chief Legal Officer | 109,711 |
| Sravan Kumar Emany | Chief Financial Officer | 105,456 |
| Graham K. Cooper | Director | 600 |
| Christi Shaw | Director | – |
| Mark Fishman | Director | 17,007 |
| Kathleen E. Walsh | Director | – |
| John Maraganore | Director | – |
| Chirfi Guindo | Director | – |
| Carole Ho | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.82M | $8.40M | $2.31M | $34 | $125 |
| FY2024 | $6.41M | $7.27M | $3.23M | $132 | $125 |
| FY2023 | $6.28M | $2.83M | $2.54M | $145 | $126 |
| FY2022 | $9.50M | -$13.94M | $3.06M | $209 | $120 |
| FY2021 | $13.91M | $17.02M | $4.74M | $425 | $134 |
| FY2020 | $906.77K | $61.90M | $3.77M | $435 | $134 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| John Evans CEO | $755.00K | – | $1.51M | $2.88M | $662.51K | $10.68K | $5.82M | -9% |
| Giuseppe Ciaramella, Ph.D. President | $668.00K | – | $683.55K | $1.30M | $495.99K | $13.56K | $3.16M | -6% |
| Sravan K. Emany CFO | $575.00K | $325.00K | – | – | $388.13K | $8.40K | $1.30M | -73% |
| Christine Bellon, Ph.D. CLO | $510.50K | – | $390.60K | $742.39K | $310.13K | $13.56K | $1.97M | -24% |
| Amy Simon, M.D. CMO | $550.00K | – | $883.58K | $1.02M | $334.13K | $13.56K | $2.80M | +7% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 7, 2020
- Offer price
- $17.00
- Securities offered
- 10,588,236
- Gross proceeds
- $180.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Aug 5, 2020
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 511 team members employed with us full-time, of which 118 had a M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 11, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 31, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 7, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 31, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?